Design of ROS-Responsive Hyaluronic Acid–Methotrexate Conjugates for Synergistic Chemo-Photothermal Therapy for Cancer
Combining chemotherapy with photothermal therapy (PTT) for cancer treatment could overcome the inherent limitations of both single-modality chemotherapy and PTT. However, the obstacle of accurate drug delivery to tumor sites based on chemo-photothermal remains challenging. This article describes dev...
Gespeichert in:
Veröffentlicht in: | Molecular pharmaceutics 2022-09, Vol.19 (9), p.3323-3335 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3335 |
---|---|
container_issue | 9 |
container_start_page | 3323 |
container_title | Molecular pharmaceutics |
container_volume | 19 |
creator | Yun, Kaiqing Guo, Juntong Zhu, Renfang Wang, Tianyi Zhang, Xiaoyan Pan, Hao Pan, Weisan |
description | Combining chemotherapy with photothermal therapy (PTT) for cancer treatment could overcome the inherent limitations of both single-modality chemotherapy and PTT. However, the obstacle of accurate drug delivery to tumor sites based on chemo-photothermal remains challenging. This article describes development of a reactive oxygen species (ROS)-responsive hyaluronic acid-based nanoparticle to overcome these drawbacks. Herein, HA-TK-MTX (HTM) was synthesized by a ROS-responsive cleaved thioketal moiety linker (TK) of methotrexate (MTX) and hyaluronic acid (HA). Through hydrophobic interaction and π–π stacking interaction, a photothermal agent IR780 was integrated into the HTM, and the IR780/HTM nanoparticles (IHTM NPs) were obtained. The IHTM NPs show high photostability, excellent photothermal performance, remarkable tumor-targeting ability, and ROS sensibility. Due to the accurate drug delivery ability and superior chemo-photothermal treatment effect of IHTM NPs, the tumor inhibition rate reached 70.95% for 4T1 tumor-bearing mice. This work serves as a precedent for the chemo-photothermal therapy of cancer by rationally designing ROS-responsive nanoparticles. |
doi_str_mv | 10.1021/acs.molpharmaceut.2c00472 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2696011825</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2696011825</sourcerecordid><originalsourceid>FETCH-LOGICAL-a340t-df2476e12e9b1c618fea15dc29c7e83c08465edb485861f6cf159e237bcb50783</originalsourceid><addsrcrecordid>eNqNkE1OwzAQRiMEEqVwh7Bjk2I7ceIsq_BTpKKitqwjx5k0qZI42A5qdtyBG3ISXFohsWM13-J9o5nnONcYTTAi-JYLPWlk3ZVcNVxAbyZEIBRE5MQZYRr4HvNjcvqbWXDuXGi9RYgElPgjZ3cHutq0rizc5WLlLUF3stXVO7izgde9km0l3Kmo8q-Pz2cwpTQKdtyAm8h2229s0m4hlbsaWlCbShuLJyU00nuxrDQl2Ltqd20n74YfNOGtAHXpnBW81nB1nGPn9eF-ncy8-eLxKZnOPe4HyHh5QYIoBEwgzrAIMSuAY5oLEosImC8QC0IKeRYwykJchKLANAbiR5nIKIqYP3ZuDns7Jd960CZtKi2grnkLstcpCeMQYcwItWh8QIWSWiso0k5VDVdDilG6t51a2-kf2-nRtu3SQ3ePbGWvWvvUP3rfaYGO1g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2696011825</pqid></control><display><type>article</type><title>Design of ROS-Responsive Hyaluronic Acid–Methotrexate Conjugates for Synergistic Chemo-Photothermal Therapy for Cancer</title><source>American Chemical Society Journals</source><creator>Yun, Kaiqing ; Guo, Juntong ; Zhu, Renfang ; Wang, Tianyi ; Zhang, Xiaoyan ; Pan, Hao ; Pan, Weisan</creator><creatorcontrib>Yun, Kaiqing ; Guo, Juntong ; Zhu, Renfang ; Wang, Tianyi ; Zhang, Xiaoyan ; Pan, Hao ; Pan, Weisan</creatorcontrib><description>Combining chemotherapy with photothermal therapy (PTT) for cancer treatment could overcome the inherent limitations of both single-modality chemotherapy and PTT. However, the obstacle of accurate drug delivery to tumor sites based on chemo-photothermal remains challenging. This article describes development of a reactive oxygen species (ROS)-responsive hyaluronic acid-based nanoparticle to overcome these drawbacks. Herein, HA-TK-MTX (HTM) was synthesized by a ROS-responsive cleaved thioketal moiety linker (TK) of methotrexate (MTX) and hyaluronic acid (HA). Through hydrophobic interaction and π–π stacking interaction, a photothermal agent IR780 was integrated into the HTM, and the IR780/HTM nanoparticles (IHTM NPs) were obtained. The IHTM NPs show high photostability, excellent photothermal performance, remarkable tumor-targeting ability, and ROS sensibility. Due to the accurate drug delivery ability and superior chemo-photothermal treatment effect of IHTM NPs, the tumor inhibition rate reached 70.95% for 4T1 tumor-bearing mice. This work serves as a precedent for the chemo-photothermal therapy of cancer by rationally designing ROS-responsive nanoparticles.</description><identifier>ISSN: 1543-8384</identifier><identifier>EISSN: 1543-8392</identifier><identifier>DOI: 10.1021/acs.molpharmaceut.2c00472</identifier><language>eng</language><publisher>American Chemical Society</publisher><ispartof>Molecular pharmaceutics, 2022-09, Vol.19 (9), p.3323-3335</ispartof><rights>2022 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a340t-df2476e12e9b1c618fea15dc29c7e83c08465edb485861f6cf159e237bcb50783</citedby><cites>FETCH-LOGICAL-a340t-df2476e12e9b1c618fea15dc29c7e83c08465edb485861f6cf159e237bcb50783</cites><orcidid>0000-0001-9060-9482</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.2c00472$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acs.molpharmaceut.2c00472$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,780,784,2765,27076,27924,27925,56738,56788</link.rule.ids></links><search><creatorcontrib>Yun, Kaiqing</creatorcontrib><creatorcontrib>Guo, Juntong</creatorcontrib><creatorcontrib>Zhu, Renfang</creatorcontrib><creatorcontrib>Wang, Tianyi</creatorcontrib><creatorcontrib>Zhang, Xiaoyan</creatorcontrib><creatorcontrib>Pan, Hao</creatorcontrib><creatorcontrib>Pan, Weisan</creatorcontrib><title>Design of ROS-Responsive Hyaluronic Acid–Methotrexate Conjugates for Synergistic Chemo-Photothermal Therapy for Cancer</title><title>Molecular pharmaceutics</title><addtitle>Mol. Pharmaceutics</addtitle><description>Combining chemotherapy with photothermal therapy (PTT) for cancer treatment could overcome the inherent limitations of both single-modality chemotherapy and PTT. However, the obstacle of accurate drug delivery to tumor sites based on chemo-photothermal remains challenging. This article describes development of a reactive oxygen species (ROS)-responsive hyaluronic acid-based nanoparticle to overcome these drawbacks. Herein, HA-TK-MTX (HTM) was synthesized by a ROS-responsive cleaved thioketal moiety linker (TK) of methotrexate (MTX) and hyaluronic acid (HA). Through hydrophobic interaction and π–π stacking interaction, a photothermal agent IR780 was integrated into the HTM, and the IR780/HTM nanoparticles (IHTM NPs) were obtained. The IHTM NPs show high photostability, excellent photothermal performance, remarkable tumor-targeting ability, and ROS sensibility. Due to the accurate drug delivery ability and superior chemo-photothermal treatment effect of IHTM NPs, the tumor inhibition rate reached 70.95% for 4T1 tumor-bearing mice. This work serves as a precedent for the chemo-photothermal therapy of cancer by rationally designing ROS-responsive nanoparticles.</description><issn>1543-8384</issn><issn>1543-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqNkE1OwzAQRiMEEqVwh7Bjk2I7ceIsq_BTpKKitqwjx5k0qZI42A5qdtyBG3ISXFohsWM13-J9o5nnONcYTTAi-JYLPWlk3ZVcNVxAbyZEIBRE5MQZYRr4HvNjcvqbWXDuXGi9RYgElPgjZ3cHutq0rizc5WLlLUF3stXVO7izgde9km0l3Kmo8q-Pz2cwpTQKdtyAm8h2229s0m4hlbsaWlCbShuLJyU00nuxrDQl2Ltqd20n74YfNOGtAHXpnBW81nB1nGPn9eF-ncy8-eLxKZnOPe4HyHh5QYIoBEwgzrAIMSuAY5oLEosImC8QC0IKeRYwykJchKLANAbiR5nIKIqYP3ZuDns7Jd960CZtKi2grnkLstcpCeMQYcwItWh8QIWSWiso0k5VDVdDilG6t51a2-kf2-nRtu3SQ3ePbGWvWvvUP3rfaYGO1g</recordid><startdate>20220905</startdate><enddate>20220905</enddate><creator>Yun, Kaiqing</creator><creator>Guo, Juntong</creator><creator>Zhu, Renfang</creator><creator>Wang, Tianyi</creator><creator>Zhang, Xiaoyan</creator><creator>Pan, Hao</creator><creator>Pan, Weisan</creator><general>American Chemical Society</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9060-9482</orcidid></search><sort><creationdate>20220905</creationdate><title>Design of ROS-Responsive Hyaluronic Acid–Methotrexate Conjugates for Synergistic Chemo-Photothermal Therapy for Cancer</title><author>Yun, Kaiqing ; Guo, Juntong ; Zhu, Renfang ; Wang, Tianyi ; Zhang, Xiaoyan ; Pan, Hao ; Pan, Weisan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a340t-df2476e12e9b1c618fea15dc29c7e83c08465edb485861f6cf159e237bcb50783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yun, Kaiqing</creatorcontrib><creatorcontrib>Guo, Juntong</creatorcontrib><creatorcontrib>Zhu, Renfang</creatorcontrib><creatorcontrib>Wang, Tianyi</creatorcontrib><creatorcontrib>Zhang, Xiaoyan</creatorcontrib><creatorcontrib>Pan, Hao</creatorcontrib><creatorcontrib>Pan, Weisan</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yun, Kaiqing</au><au>Guo, Juntong</au><au>Zhu, Renfang</au><au>Wang, Tianyi</au><au>Zhang, Xiaoyan</au><au>Pan, Hao</au><au>Pan, Weisan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design of ROS-Responsive Hyaluronic Acid–Methotrexate Conjugates for Synergistic Chemo-Photothermal Therapy for Cancer</atitle><jtitle>Molecular pharmaceutics</jtitle><addtitle>Mol. Pharmaceutics</addtitle><date>2022-09-05</date><risdate>2022</risdate><volume>19</volume><issue>9</issue><spage>3323</spage><epage>3335</epage><pages>3323-3335</pages><issn>1543-8384</issn><eissn>1543-8392</eissn><abstract>Combining chemotherapy with photothermal therapy (PTT) for cancer treatment could overcome the inherent limitations of both single-modality chemotherapy and PTT. However, the obstacle of accurate drug delivery to tumor sites based on chemo-photothermal remains challenging. This article describes development of a reactive oxygen species (ROS)-responsive hyaluronic acid-based nanoparticle to overcome these drawbacks. Herein, HA-TK-MTX (HTM) was synthesized by a ROS-responsive cleaved thioketal moiety linker (TK) of methotrexate (MTX) and hyaluronic acid (HA). Through hydrophobic interaction and π–π stacking interaction, a photothermal agent IR780 was integrated into the HTM, and the IR780/HTM nanoparticles (IHTM NPs) were obtained. The IHTM NPs show high photostability, excellent photothermal performance, remarkable tumor-targeting ability, and ROS sensibility. Due to the accurate drug delivery ability and superior chemo-photothermal treatment effect of IHTM NPs, the tumor inhibition rate reached 70.95% for 4T1 tumor-bearing mice. This work serves as a precedent for the chemo-photothermal therapy of cancer by rationally designing ROS-responsive nanoparticles.</abstract><pub>American Chemical Society</pub><doi>10.1021/acs.molpharmaceut.2c00472</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0001-9060-9482</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1543-8384 |
ispartof | Molecular pharmaceutics, 2022-09, Vol.19 (9), p.3323-3335 |
issn | 1543-8384 1543-8392 |
language | eng |
recordid | cdi_proquest_miscellaneous_2696011825 |
source | American Chemical Society Journals |
title | Design of ROS-Responsive Hyaluronic Acid–Methotrexate Conjugates for Synergistic Chemo-Photothermal Therapy for Cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T14%3A57%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design%20of%20ROS-Responsive%20Hyaluronic%20Acid%E2%80%93Methotrexate%20Conjugates%20for%20Synergistic%20Chemo-Photothermal%20Therapy%20for%20Cancer&rft.jtitle=Molecular%20pharmaceutics&rft.au=Yun,%20Kaiqing&rft.date=2022-09-05&rft.volume=19&rft.issue=9&rft.spage=3323&rft.epage=3335&rft.pages=3323-3335&rft.issn=1543-8384&rft.eissn=1543-8392&rft_id=info:doi/10.1021/acs.molpharmaceut.2c00472&rft_dat=%3Cproquest_cross%3E2696011825%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2696011825&rft_id=info:pmid/&rfr_iscdi=true |